KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Retained Earnings (2016 - 2025)

Astrazeneca (AZN) has 3 years of Retained Earnings data on record, last reported at $11.0 billion in Q4 2025.

  • For Q4 2025, Retained Earnings rose 247.22% year-over-year to $11.0 billion; the TTM value through Dec 2025 reached $11.0 billion, up 247.22%, while the annual FY2025 figure was $11.0 billion, 247.22% up from the prior year.
  • Retained Earnings reached $11.0 billion in Q4 2025 per AZN's latest filing, up from $3.2 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $11.0 billion in Q4 2025 and bottomed at $1.5 billion in Q4 2023.
  • Average Retained Earnings over 3 years is $5.2 billion, with a median of $3.2 billion recorded in 2024.
  • Peak YoY movement for Retained Earnings: surged 110.39% in 2024, then surged 247.22% in 2025.
  • A 3-year view of Retained Earnings shows it stood at $1.5 billion in 2023, then soared by 110.39% to $3.2 billion in 2024, then soared by 247.22% to $11.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were $11.0 billion in Q4 2025, $3.2 billion in Q4 2024, and $1.5 billion in Q4 2023.